Furthermore, 18F-PSMA-1007 demonstrates remarkable specificity (85–92%) and selectivity for locoregional lymph node metastases, significantly improving diagnostic confidence in staging and restaging prostate cancer [112]. This evidence concerns the gene FOLH1 and prostate cancer.